Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
JJohnson & Johnson logo
JNJNYSE

Johnson & Johnson

Johnson & Johnson
Loading price data…
Loading price data…
Chart type
Interval
Moving averages
Up/down colors

Share screenshot

Recent & upcoming events

Aug 25
Ex-dividend Time TBD
Ex-dividend (predicted) $1.34
Add to Google Calendar
Jul 24
Filing Time TBD
Quarterly report (10-Q) filing due (est.)
Add to Google Calendar
Jul 15
Earnings 7:00
Q2 earnings
Add to Google Calendar
Apr 14
Earnings Time TBD
Full-year earnings
Add to Google Calendar
Jan 21
Earnings Time TBD
Q3 earnings
Add to Google Calendar
2025
Oct 14
Earnings Time TBD
Q2 earnings
Add to Google Calendar
Jul 16
Earnings Time TBD
Q1 earnings
Add to Google Calendar
Apr 15
Earnings Time TBD
Full-year earnings
Add to Google Calendar
Oct 14
Est.
Earnings 7:35 approx.
Q3 earnings (predicted)
Add to Google Calendar
Nov 24
Est.
Ex-dividend Time TBD
Ex-dividend (predicted) $1.34
Add to Google Calendar
2027
Jan 13
Est.
Earnings 7:35 approx.
FY earnings (predicted)
Add to Google Calendar
Feb 15
Est.
Filing Time TBD
Annual report (10-K) filing due (est.)
Add to Google Calendar
Apr 28
Est.
Shareholder meeting Time TBD
Annual meeting (est.)
Add to Google Calendar

KPI highlights

FY25
Revenue $94.19B YoY +6.0%
Operating income $25.60B margin 27.2%
Net income $26.80B YoY +90.6%
EPS $11.13 YoY +90.6%
P/E 30.6× Slightly rich Rough PER guide (a simplified band — fair value varies by industry and growth stage): <10 Cheap / 10–15 Slightly cheap / 15–22 Fair / 22–35 Slightly rich / ≥35 Rich
ROE —

Quarterly earnings / EPS

Reported actuals & surprise
Next earnings (scheduled) Oct 14, 2026 Forward EPS estimate not stored
QuarterEst. EPSActual EPSSurprise
Oct 14, 2025 $0.66 $0.69 Beat +4.5%
Jan 21, 2026 — — —
Apr 14, 2026 $2.68 $2.70 Beat +0.8%
Jul 15, 2026 $2.85 $2.90 Beat +1.8%

Quarterly fundamentals

Income & cash flow Unit: $1M
Quarter FY25 Q1FY25 Q2FY25 Q3FY25 Q4FY26 Q1FY26 Q2
Revenue 21,89323,74323,99324,56424,06225,310
Operating income 6,1996,7107,0965,5916,3957,174
Net income 10,9995,5375,1525,1165,2355,534
Operating CF 6,3492,6307,1456,0896,3945,527

Company news

Aug 24, 2026 FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients Jul 30, 2026 Johnson &amp; Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer May 31, 2026 RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited May 31, 2026 Johnson &amp; Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2013–2026）

機関投資家 59.5%未開示 40.5%20132015201720192021202320252026
機関投資家 59.5%未開示 40.5%13Q114Q215Q316Q418Q119Q220Q321Q423Q124Q225Q426Q1
機関投資家未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

BlackRock, Inc. 7.5%BlackRock, Inc.VANGUARD CAPITAL M 5.5%VANGUARD CAPITAL MANAGEMENT LLCSTATE STREET CORP 4.7%STATE STREET CORPVANGUARD PORTFOLIO 2.2%VANGUARD PORTFOLIO MANAGEMENT LLCGEODE CAPITAL MANA 2.1%GEODE CAPITAL MANAGEMENT, LLCMORGAN STANLEY 1.6%MORGAN STANLEYSTATE FARM MUTUAL 1.1%STATE FARM MUTUAL AUTOMOBILE INSURANCE CONORTHERN TRUST COR 1%NORTHERN TRUST CORPBANK OF AMERICA CO 0.9%BANK OF AMERICA CORP /DE/20132015201720192021202320252026
BlackRock, Inc. 7.5%BlackRock, Inc.VANGUARD CAPITAL M 5.5%VANGUARD CAPITAL MANAGEMENT LLCSTATE STREET CORP 4.7%STATE STREET CORPVANGUARD PORTFOLIO 2.2%VANGUARD PORTFOLIO MANAGEMENT LLCGEODE CAPITAL MANA 2.1%GEODE CAPITAL MANAGEMENT, LLCMORGAN STANLEY 1.6%MORGAN STANLEYSTATE FARM MUTUAL 1.1%STATE FARM MUTUAL AUTOMOBILE INSURANCE CONORTHERN TRUST COR 1%NORTHERN TRUST CORPBANK OF AMERICA CO 0.9%BANK OF AMERICA CORP /DE/13Q114Q215Q316Q418Q119Q220Q321Q423Q124Q225Q426Q1

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
その他機関投資家（13F 4475社） 649,672,181 23.0% 13F
BlackRock, Inc. 213,385,546 7.5% 13F
VANGUARD CAPITAL MANAGEMENT LLC 156,605,370 5.5% 13F
STATE STREET CORP 133,476,288 4.7% 13F
VANGUARD PORTFOLIO MANAGEMENT LLC 63,514,436 2.2% 13F
GEODE CAPITAL MANAGEMENT, LLC 59,164,862 2.1% 13F
MORGAN STANLEY 44,721,167 1.6% 13F
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 31,590,952 1.1% 13F
NORTHERN TRUST CORP 29,319,669 1.0% 13F
BANK OF AMERICA CORP /DE/ 25,516,697 0.9% 13F
FMR LLC 24,771,828 0.9% 13F
Bank of New York Mellon Corp 21,821,962 0.8% 13F
WELLINGTON MANAGEMENT GROUP LLP 20,075,375 0.7% 13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 19,628,113 0.7% 13F
Legal & General Group Plc 19,347,862 0.7% 13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 19,177,219 0.7% 13F
GOLDMAN SACHS GROUP INC 18,057,047 0.6% 13F
WELLS FARGO & COMPANY/MN 16,925,454 0.6% 13F
PRICE T ROWE ASSOCIATES INC /MD/ 16,491,133 0.6% 13F
DIMENSIONAL FUND ADVISORS LP 15,832,514 0.6% 13F
Invesco Ltd. 15,046,905 0.5% 13F
DEUTSCHE BANK AG\ 14,435,647 0.5% 13F
AMERIPRISE FINANCIAL INC 13,779,406 0.5% 13F
VANGUARD FIDUCIARY TRUST CO 13,564,489 0.5% 13F
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 13,434,302 0.5% 13F
Amundi 13,406,820 0.5% 13F

Source：SEC EDGAR（DEF 14A・13D/G・13F）　Classification inferred from disclosed names

F-Score (Piotroski)

3/9 1 of 9 items lack data

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 13.5%
✓ Positive operating cash flow $22.21B
✗ ROA improved YoY 13.5% → 13.5%
✗ Operating CF exceeds net income (accrual quality) OCF $22.21B / net income $26.80B
— Equity ratio improved* Substitute for the original “decrease in long-term debt” No data
✗ Current ratio improved 1.03× → 1.03×
✓ No dilution (shares outstanding did not increase) 2,409,898,936 → 2,407,400,000
✗ Gross margin improved 67.9% → 67.9%
✗ Asset turnover improved 0.47× → 0.47×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY25
Equity ratio —
Current ratio 1.0×
Years of positive operating CF 12 of last 12 yrs
Payout ratio 61%
Latest fiscal year result Profit (net income $26.80B)

Performance history

Last 10 years
$0.0B$23.5B$47.1B$70.6B$94.2B FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

Income & assets

Unit: $1M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue 71,89076,45081,58182,05982,58478,74079,99085,15988,82194,193
Operating income ————19,73320,94322,21323,40921,24925,596
Ordinary income ——————————
Net income 16,5401,30015,29715,11914,71420,87817,94135,15314,06626,804
Total assets 141,208157,303152,954157,728174,894182,018187,378167,558180,104199,210
Equity ——————————

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Indicators & cash flow

Unit: $1M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
EPS $6.04$0.48$5.70$5.72$5.59$7.93$6.83$13.88$5.84$11.13
ROE ——————————
Operating CF 18,76721,05622,20123,41623,53623,41021,19422,79124,26624,530
Investing CF -4,761-14,868-3,167-6,194-20,825-8,683-12,371878-18,599-23,588
Financing CF -8,551-7,673-18,510-18,015-6,120-14,047-8,871-15,825-3,132-5,539
FCF ————20,18919,75817,18517,77818,05919,313

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Source: SEC EDGAR (10-K, etc.) (fetched 2026-07-03) *Some metrics supplemented from additional sources

Key financial metrics

High ROE ✓

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data